Diabetische Nephropathie

M. Morcos; M. Zeier; V. Schwenger

doi:10.1055/s-2007-979378

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2007; 132(19): 1039-1042
DOI: 10.1055/s-2007-979378

Aktuelle Diagnostik & Therapie | Review article

Diabetologie, Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Diabetische Nephropathie

Diabetic nephropathyM. Morcos¹ , M. Zeier¹ , V. Schwenger¹

¹Abteilung für Innere Medizin 1, Endokrinologie, Stoffwechsel und Klinische Chemie, Medizinische Universitätsklinik Heidelberg und Sektion Nephrologie, Medizinische Universitätsklinik Heidelberg

Abstract

Schlüsselwörter

Diabetische Nephropathie - Kardiovaskuläres Risiko - Nierenersatztherapie - Multifaktorieller Ansatz - RAAS-Hemmung - Insulintherapie

Key words

diabetic nephropathy - kidney replacement therapy - cardiovascular risk - multifactorial intervention - RAAS-Inhibition - insulin therapy

Full Text

References

Literatur

1 Basi S, Lewis J B. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis. 2006; 47 927-946
2 Casas J P, Chua W, Loukogeorgakis S, Vallance P. et al . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes. Lancet. 2005; 366 2026-2033
3 Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361 2005-2016
4 Gaede P, Vedel P, Larsen N. et al . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348 383-393
5 Haller H, Viberti G C, Mimran A. et al . Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006; 24 403
6 MacKinnon M, Shurraw S, Akbari A. et al . Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006; 48 8-20
7 Mogensen C E. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction. BMJ. 1998; 317 693-694
8 National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification stratification. Am J Kidney Dis. 2002; (2 Suppl 1) 39 S1-266
9 Parving H H, Lehnert H, Brochner-Mortensen J. et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345 870-878
10 Praxis Leitlinien der Deutschen Diabetes-Gesellschaft (DDG) . Diabetische Nephropathie. Diabetes und Stoffwechsel. 2002; (Suppl 2) 17-19
11 Rachmani R, Levi Z, Lidar M. et al . Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract. 2000; 49 187-194
12 Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol. 2006; 2 562-567
13 Ritz E, Orth S R. Nephropathy in patients with type 2 diabetes mellitus (Review: No abstract available). N Engl J Med. 1999; 341 1127-1133
14 Ritz E, Schwenger V. Lifestyle modification and progressive renal failure. Nephrology (Carlton). 2005; 10 387-392
15 Rossing P, Parving H H, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction?. Nephrol Dial Transplant. 2006; 21 2354-2357
16 Skrivarhaug T, Bangstad H J, Stene L C, Sandvik L, Hanssen K F, Joner G. Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatr Diabetes. 2006; 7 239-246
17 The Diabetes Control and Complications Trial . Retinopathy and Nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342 381-389
18 Toeller M, Buyken A, Heitkamp G. et al . Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997; 40 1219-1226
19 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 837
20 Wanner C, Krane V, Marz W. et al. Deutsche Diabetes-Dialyse-Studie (4D) Study Group . Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study). Kidney Blood Press Res. 2004; 27 259-266

Dr. Michael Morcos

Innere Medizin 1, Medizinische Universitätsklinik

INF 410

69120 Heidelberg

Phone: 06221-568614

Fax: 06221-566848

Email: Michael.Morcos@med.uni-heidelberg.de